Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Methotrexate in Elderly/Frail HNSCC
NCT03193931Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Feb 2018
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Antitumor activity of pembrolizumab in SCCHN at 1 year. Started Feb 2018; status: terminated.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03193931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193931.